Contact Us

A note to patients: Vaxil frequently receives requests from patients seeking our experimental drugs. Please keep in mind that Vaxil’s products remain unproven, investigational and in clinical trial phases. Unfortunately, Vaxil therefore does NOT have the ability to sell or give away any of its drugs. Furthermore, at the time, Vaxil does not have any ongoing clinical trials recruiting patients. We are doing our best to advance our pipeline of drugs, but it is a lengthy process and Vaxil adheres closely to drug development regulations.

Wishing you the very best,

The Vaxil Team

VAXIL – Creating the ideal immunotherapy

Inducing a Broad


Learn More



Learn More


Cancer Resistance

Learn More

Harnessing Potent

Immune Response

Learn More



Learn More

Expression on

Cancer Stem Cells

Learn More



Learn More

First Ever SP-Specific

Antibody Platform

Learn More

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is ​its ImMucin™ ​lead immunotherapy product.